Showing 5921-5930 of 6035 results for "".
- Oyster Point Announces Positive Results from Phase 2 Clinical Trial of Investigational Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-announces-positive-results-from-phase-2-clinical-trial-of-investigational-treatment-for-dry-eye-disease/2480029/Oyster Point Pharma announced results from the PEARL study, a phase 2b clinical trial evaluating the company’s novel therapy for the treatment of dry eye disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a v
- Some AMD Patients May Not Respond to Intravitreal Aflibercepthttps://modernod.com/news/some-amd-patients-may-not-respond-to-intravitreal-aflibercept/2480030/Although intravitreal aflibercept is effective in the great majority of treatment-naive cases of neovascular age-related macular degeneration (AMD), the drug may not work for a small subgroup of patients with choroidal vascular hyperpermeability, Japanese researchers say, according to a
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- Oculocare’s Alleye Receives FDA 510(k) Clearance for Monitoring Eyesight in AMDhttps://modernod.com/news/oculocares-alleye-receives-fda-510k-clearance-for-monitoring-eyesight-in-amd/2480036/Oculocare Medical announced the FDA 510(k) clearance of Alleye, a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD). Alleye is designed to detect and characterize central and paracentral metamorphopsia (visual distortio
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Katena Products Announces the Acquisition of Blink Medicalhttps://modernod.com/news/katena-products-announces-the-acquisition-of-blink-medical/2480044/Katena Products announced the purchase of Blink Medical, a UK-based provider of primarily single use ophthalmic instruments. Terms of the deal were not announced. Founded in 2004, Blink Medical currently distributes its products within Europe and the Middle East.
- Novartis Chairman Says Alcon Worth $20 Billion to $30 Billion: Finanz und Wirtschafthttps://modernod.com/news/novartis-chairman-says-alcon-worth-20-billion-30-billion-finanz-und-wirtschaft/2480052/The chairman of Swiss Novartis expects Alcon to be valued at between $20 billion and $30 billion when the ophthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft, according to a Reuters
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s